2 active not recruiting, 2 completed, 2 recruiting, 2 terminated. 7 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 2, Terminated 2, Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Terminated 2, Completed 1, Recruiting 1 |
Follow Unresectable Leiomyosarcoma: new trials by email Literature Review of Unresectable Leiomyosarcoma trials Research Report on Unresectable Leiomyosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma Biospecimen Collection, Computed Tomography, Echocardiography - Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma | Phase 2 | Recruiting | Northwestern University | 73 | 2024-09-19 | 2026-10-13 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-02-06 | 2026-11-04 |
| Niraparib for the Treatment of Leiomyosarcoma Niraparib Tosylate Monohydrate - Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma | Phase 2 | Withdrawn | David Liebner, MD | 2023-12-01 | 2023-09-18 | |
| Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma Biopsy Procedure, Biospecimen Collection, Cabozantinib - Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma | Phase 2 | Active not recruiting | National Cancer Institute LAO | 66 | 2023-10-25 | 2026-10-09 |
| Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma Cabozantinib, Quality-of-Life Assessment, Questionnaire Administration - Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 96 | 2020-01-22 | 2026-11-03 |
| Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery Avelumab, Trabectedin - Metastatic Leiomyosarcoma, Metastatic Liposarcoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 35 | 2017-09-28 | 2022-04-29 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 16 | 2017-03-10 | 2023-08-16 |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 151 | 2015-11-30 | 2022-08-23 |
| Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2015-05-19 | 2025-02-25 |
Leiomyosarcoma (7) · Histiocytoma, Malignant Fibrous (4) · Sarcoma (4) · Sarcoma, Synovial (4) · Dermatofibrosarcoma (3) · Liposarcoma (3) · Neurofibrosarcoma (2) · Bone Neoplasms (1) · Disorders of Sex Development (1) · Fibrosarcoma (1) · Hemangiosarcoma (1) · Osteosarcoma (1) · Sarcoma, Ewing (1)
Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Connective and Soft Tissue (9) · Neoplasms, Muscle Tissue (7) · Neoplasms, Connective Tissue (5) · Sarcoma (5) · Histiocytoma (4) · Neoplasms, Fibrous Tissue (4) · Neoplasms, Adipose Tissue (3) · Fibrosarcoma (2) · Neoplasms, Nerve Tissue (2) · Nerve Sheath Neoplasms (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Neurofibroma (2)
Specimen Handling (3) · Biopsy (2) · CTLA-4 Antigen (2) · Doxorubicin (2) · Ipilimumab (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · cabozantinib (2) · Temozolomide (1) · Trabectedin (1) · avelumab (1) · liposomal doxorubicin (1) · niraparib (1) · pazopanib (1) · peposertib (1)
National Cancer Institute (NCI) (3) · City of Hope Medical Center (1) · David Liebner, MD (1) · Fred Hutchinson Cancer Center (1) · National Cancer Institute LAO (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1)
United States (8) · Canada (1)
A P Chen (1) · Candace L Haddox (1) · David Liebner, MD (1) · Janet Yoon, MD (1) · Lara E Davis (1) · Pedro Hermida de Viveiros, MD (1) · Seth Pollack (1) · Suzanne George (1) · William D Tap (1)
P30CA060553 (2), UM1CA186709 (2), P30CA015704 (1), U10CA180821 (1)